Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Target Price at $105.80

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $105.80.

Several brokerages have recently commented on LMAT. Wells Fargo & Company raised their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Roth Mkm restated a “buy” rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Barrington Research lifted their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st.

LeMaitre Vascular Stock Up 0.5%

Shares of NASDAQ LMAT opened at $113.45 on Thursday. LeMaitre Vascular has a one year low of $78.01 and a one year high of $118.01. The firm’s 50 day simple moving average is $107.21 and its two-hundred day simple moving average is $93.27. The stock has a market capitalization of $2.59 billion, a P/E ratio of 45.20, a PEG ratio of 3.25 and a beta of 0.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period in the previous year, the business earned $0.49 earnings per share. LeMaitre Vascular’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, analysts expect that LeMaitre Vascular will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.9%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio (DPR) is 39.84%.

Insiders Place Their Bets

In other news, CEO George W. Lemaitre sold 150,000 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $106.76, for a total value of $16,014,000.00. Following the sale, the chief executive officer directly owned 1,532,304 shares in the company, valued at $163,588,775.04. The trade was a 8.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the sale, the insider owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 215,438 shares of company stock valued at $23,062,911 in the last three months. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors have recently modified their holdings of the stock. Livet Wealth LLC purchased a new stake in LeMaitre Vascular during the 1st quarter valued at $227,000. Conestoga Capital Advisors LLC boosted its stake in LeMaitre Vascular by 3.6% during the first quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after buying an additional 51,825 shares during the period. James Investment Research Inc. bought a new position in LeMaitre Vascular during the first quarter valued at $243,000. Pictet Asset Management Holding SA raised its stake in shares of LeMaitre Vascular by 5.5% in the first quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock valued at $356,000 after acquiring an additional 169 shares during the period. Finally, Wesbanco Bank Inc. raised its stake in shares of LeMaitre Vascular by 13.8% in the first quarter. Wesbanco Bank Inc. now owns 19,800 shares of the medical instruments supplier’s stock valued at $2,162,000 after acquiring an additional 2,400 shares during the period. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.